Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration

Oncotarget

Volumn 6, Issue 5, 2015, Pages 2981-2991

  Zumwalt, Timothy J ^a,b,c   Arnold, Mildred ^a   Goel, Ajay ^a   Boland, C Richard ^a  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b BAYLOR UNIVERSITY   (United States)

^c BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

Author keywords

Chemokine; Colorectal cancer; Cytotoxic t lymphocyte; Helper t cell; Immune cell

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANZYME B; RANTES; CCL5 PROTEIN, HUMAN; CXCL10 PROTEIN, HUMAN; GRANZYME; GZMB PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CHEMOTAXIS; COLORECTAL CANCER; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR CELL; TUMOR IMMUNITY; TUMOR INVASION; TUMOR MICROENVIRONMENT; AGED; CELL COMMUNICATION; COLORECTAL TUMOR; ENZYMOLOGY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HELPER CELL; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NEUTROPHIL CHEMOTAXIS; PHENOTYPE; PROCEDURES; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; VERY ELDERLY;

ADAPTIVE IMMUNITY; AGED; AGED, 80 AND OVER; CELL COMMUNICATION; CHEMOKINE CCL5; CHEMOKINE CXCL10; CHEMOTAXIS, LEUKOCYTE; COLORECTAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANZYMES; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84923311842     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3205     Document Type: Article

References (39)

1. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J.Clin.Pathol. 1986; 39: 585-589.
2. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N.Engl.J.Med. 2005; 353: 2654-2666.
3. Fridman WH, Galon J, Dieu-Nosjean MC, Cremer I, Fisson S, Damotte D, Pages F, Tartour E, Sautes-Fridman C. Immune infiltration in human cancer: prognostic significance and disease control. Curr.Top.Microbiol. Immunol. 2011; 344: 1-24.
4. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010; 29: 1093-1102.
5. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, et al. In situ cytotoxic and memory T cells predict outcome in patients with earlystage colorectal cancer. J.Clin.Oncol. 2009; 27: 5944-5951.
6. Pages F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J.Leukoc. Biol. 2008; 84: 981-987.
7. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007; 67: 1883-1886.
8. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313: 1960-1964.
9. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH, Pages F, Trajanoski Z, Galon J. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010; 138: 1429-1440.
10. Taylor CR and Levenson RM. Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006; 49: 411-424.
11. Schoenborn JR and Wilson CB. Regulation of interferongamma during innate and adaptive immune responses. Adv. Immunol. 2007; 96: 41-101.
12. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat.Rev.Immunol. 2006; 6: 836-848.
13. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu.Rev. Immunol. 2003; 21: 713-758.
14. Balkwill F. Cancer and the chemokine network. Nat.Rev. Cancer. 2004; 4: 540-550.
15. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, Sahagan BG, Neote K. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J.Exp.Med. 1998; 187: 2009-2021.
16. Groom JR and Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol.Cell Biol. 2011; 89: 207-215.
17. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J.Exp.Med. 1998; 187: 129-134.
18. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, Dayer JM. CCR5 is characteristic of Th1 lymphocytes. Nature. 1998; 391: 344-345.
19. Kim CH, Nagata K, Butcher EC. Dendritic cells support sequential reprogramming of chemoattractant receptor profiles during naive to effector T cell differentiation. J.Immunol. 2003; 171: 152-158.
20. Erreni M, Bianchi P, Laghi L, Mirolo M, Fabbri M, Locati M, Mantovani A, Allavena P. Expression of chemokines and chemokine receptors in human colon cancer. Methods Enzymol. 2009; 460: 105-121.
21. Musha H, Ohtani H, Mizoi T, Kinouchi M, Nakayama T, Shiiba K, Miyagawa K, Nagura H, Yoshie O, Sasaki I. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int.J.Cancer. 2005; 116: 949-956.
22. Zimmermann T, Moehler M, Gockel I, Sgourakis GG, Biesterfeld S, Muller M, Berger MR, Lang H, Galle PR, Schimanski CC. Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration. Int.J.Colorectal Dis. 2010; 25: 417-424.
23. Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, Kirilovsky A, Lagorce C, Bindea G, Ferariu D, Danciu M, Bruneval P, Scripcariu V, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin.Cancer Res. 2014; 20: 1891-1899.
24. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat.Med. 2013; 19: 619-625.
25. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat.Rev.Immunol. 2006; 6: 715-727.
26. Nagtegaal ID, Tot T, Jayne DG, McShane P, Nihlberg A, Marshall HC, Pahlman L, Brown JM, Guillou PJ, Quirke P. Lymph nodes, tumor deposits, and TNM: are we getting better? J.Clin.Oncol. 2011; 29: 2487-2492.
27. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J.Pathol. 2014; 232: 199-209.
28. Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The Cancer Genome Atlas Pan-Cancer analysis project. Nat.Genet. 2013; 45: 1113-1120.
29. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Osterreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012; 491: 254-258.
30. Straus DS. TNFalpha and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. Mol.Cancer. 2013; 12: 78-4598-12-78.
31. Kahn KL, Adams JL, Weeks JC, Chrischilles EA, Schrag D, Ayanian JZ, Kiefe CI, Ganz PA, Bhoopalam N, Potosky AL, Harrington DP, Fletcher RH. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA. 2010; 303: 1037-1045.
32. Nagaraj S and Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008; 68: 2561-2563.
33. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rebe C, Ghiringhelli F. 5-Fluorouracil selectively kills tumor-associated myeloidderived suppressor cells resulting in enhanced T celldependent antitumor immunity. Cancer Res. 2010; 70: 3052-3061.
34. Kanterman J, Sade-Feldman M, Biton M, Ish-Shalom E, Lasry A, Goldshtein A, Hubert A, Baniyash M. Adverse Immunoregulatory Effects of 5FU and CPT11 Chemotherapy on Myeloid-Derived Suppressor Cells and Colorectal Cancer Outcomes. Cancer Res. 2014; 74: 6022-6035.
35. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. The human genome browser at UCSC. Genome Res. 2002; 12: 996-1006.
36. Spandidos A, Wang X, Wang H, Seed B. PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res. 2010; 38: D792-9.
37. Wang X and Seed B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res. 2003; 31: e154.
38. Pattyn F, Robbrecht P, De Paepe A, Speleman F, Vandesompele J. RTPrimerDB: the real-time PCR primer and probe database, major update 2006. Nucleic Acids Res. 2006; 34: D684-8.
39. Wessa P. Hierarchical Clustering (v1.0.3) in Free Statistics Software (v1.1.23-r7). Office for Research Development and Education. 2012; URL http://www.wessa.net/rwasp_ hierarchicalclustering.wasp/.